Latest news and press releases about Evogene Ltd. (EVGN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform.
Price
| Price | $0.50 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| Price / Book | -1.98 |
| EV / EBITDA | 0.19 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 766.01% |
| Return on Invested Capital | -121.41% |
| Return on Assets | -68.20% |
| Gross Margin | -14.16% |
| Operating Margin | -1020.35% |
| Net Margin | -696.26% |
Related companies: AEON · BOLT · CING · CLRB · COCP · DWTX · GLTO
Explore sector: Healthcare · Biotechnology
More sections of EVGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks